Menu Search
Equities

Globus Medical Inc

GMED:NYQ

Globus Medical Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)84.49
  • Today's Change-0.23 / -0.27%
  • Shares traded1.14m
  • 1 Year change+82.41%
  • Beta1.1855
Data delayed at least 15 minutes, as of Nov 26 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy3
Outperform7
Hold5
Sell1
Strong Sell0

Share price forecast in USD

The 13 analysts offering 12 month price targets for Globus Medical Inc have a median target of 88.00, with a high estimate of 100.00 and a low estimate of 80.00. The median estimate represents a 4.15% increase from the last price of 84.49.
High18.4%100.00
Med4.2%88.00
Low-5.3%80.00

Earnings history & estimates in USD

On Nov 05, 2024, Globus Medical Inc reported 3rd quarter 2024 earnings of 0.83 per share. This result exceeded the 0.65 consensus of the 15 analysts covering the company and exceeded last year's 3rd quarter results by 45.61%.
The next earnings announcement is expected on Feb 18, 2025.
Average growth rate+10.02%
Globus Medical Inc reported annual 2023 earnings of 2.32 per share on Feb 20, 2024.
Average growth rate+10.25%
More ▼

Revenue history & estimates in USD

Globus Medical, Inc. had 3rd quarter 2024 revenues of 625.71m. This bettered the 603.93m consensus of the 14 analysts covering the company. This was 126.14% above the prior year's 3rd quarter results.
Average growth rate+15.57%
Globus Medical, Inc. had revenues for the full year 2023 of 1.57bn. This was 53.34% above the prior year's results.
Average growth rate+20.50%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.